[HTML][HTML] Current trends in diagnosis and management of follicular lymphoma
Follicular lymphoma (FL) originates from germinal center B cells, is the most prevalent form
of indolent non-Hodgkin's lymphoma. Upfront management is based on stage, grade, and …
of indolent non-Hodgkin's lymphoma. Upfront management is based on stage, grade, and …
Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta‐analysis of randomized …
Y Chu, Y Liu, Z Yu, L Zhan, T Lu, Y Jiang, X Fang… - Cancer, 2024 - Wiley Online Library
Background The emergence of novel and efficient antibody maintenance approaches has
provided more options for post‐induction treatment of advanced follicular lymphoma (FL) …
provided more options for post‐induction treatment of advanced follicular lymphoma (FL) …
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study
PURPOSE Rituximab improves progression-free survival (PFS) and time to next treatment
(TTNT) when compared with the watch and wait strategy for patients with low–tumor burden …
(TTNT) when compared with the watch and wait strategy for patients with low–tumor burden …
Chemotherapy-free management of follicular and marginal zone lymphoma
TA Ollila, AJ Olszewski - Cancer Management and Research, 2021 - Taylor & Francis
Many patients with follicular (FL) or marginal zone lymphoma (MZL) are not eligible to
receive immunochemotherapy due to advanced age or comorbidities. Recent innovations in …
receive immunochemotherapy due to advanced age or comorbidities. Recent innovations in …
[HTML][HTML] Validity of event-free survival as a surrogate endpoint in haematological malignancy: review of the literature and health technology assessments
S Assouline, A Wiesinger, C Spooner… - Critical Reviews in …, 2022 - Elsevier
Objective Event-free survival (EFS) is increasingly used as a primary endpoint in trials of
haematological malignancies (HMs). A key consideration is whether EFS can reliably predict …
haematological malignancies (HMs). A key consideration is whether EFS can reliably predict …
Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance
JWD Tobin, G Hapgood, A Johnston… - Internal Medicine …, 2024 - Wiley Online Library
Follicular lymphoma (FL) is the most common indolent non‐Hodgkin lymphoma subtype,
accounting for 15–20% of all lymphoma diagnoses. Although typically slow‐growing and …
accounting for 15–20% of all lymphoma diagnoses. Although typically slow‐growing and …
Recent advances in the management of patients with relapsed/refractory follicular lymphoma
G Pongas, B Cheson - Blood and Lymphatic Cancer: Targets and …, 2021 - Taylor & Francis
Advanced follicular lymphoma (FL) often relapses after front-line chemoimmunotherapy, and
many patients will eventually require subsequent therapy. In 2021, two new therapies were …
many patients will eventually require subsequent therapy. In 2021, two new therapies were …
Treatment with idelalisib in patients with relapsed or refractory follicular lymphoma: The observational Italian multicenter FolIdela Study
B Casadei, L Argnani, A Broccoli, C Patti, PM Stefani… - Cancers, 2022 - mdpi.com
Simple Summary Idelalisib, the first-in-class phosphatidylinositol 3-kinase inhibitor,
approved by the Italian Medicines Agency for the treatment of relapsed/refractory follicular …
approved by the Italian Medicines Agency for the treatment of relapsed/refractory follicular …
Phase III clinical trials in first-line follicular lymphoma: A review of their design and interpretation
E Bachy, K Rufibach, J Parreira, A Launonen… - Advances in …, 2021 - Springer
Follicular lymphoma (FL) is one of the most common subtypes of non-Hodgkin lymphoma
worldwide. Improved survival outcomes with rituximab-based therapy in clinical trials led to …
worldwide. Improved survival outcomes with rituximab-based therapy in clinical trials led to …
Robustness and pragmatism of the evidence supporting the European Society for Medical Oncology guidelines for the diagnosis, treatment, and follow-up of follicular …
M Sorigue, O Kuittinen - Expert Review of Hematology, 2021 - Taylor & Francis
Background: Results of randomized clinical trials may not be entirely applicable to clinical
practice. The present manuscript aims to explore the pragmatism and robustness of the …
practice. The present manuscript aims to explore the pragmatism and robustness of the …